Edwards Lifesciences Corporation (EW) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Edwards Lifesciences Corporation (EW) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Edwards Lifesciences Corporation (EW) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript
Edwards Lifesciences Corporation (EW) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript
Edwards Lifesciences scraps anti-copycat policy, EU drops antitrust investigation
U.S. medical device maker Edwards Lifesciences has scrapped its anti-copycat policy that triggered a complaint from an Indian rival, EU antitrust regulators said on Monday as they closed their investigation into the company.
EW's Q4 Earnings Miss Estimates, Revenues Up Y/Y, Stock Climbs
Edwards' Q4 EPS lags estimates but revenues top as TAVR and TMTT surge. Shares rise with 2026 sales growth seen at 8%-10%.
Edwards Lifesciences Corporation (EW) Q4 2025 Earnings Call Transcript
Edwards Lifesciences Corporation (EW) Q4 2025 Earnings Call Transcript
Compared to Estimates, Edwards Lifesciences (EW) Q4 Earnings: A Look at Key Metrics
The headline numbers for Edwards Lifesciences (EW) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ahead of Edwards Lifesciences (EW) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Evaluate the expected performance of Edwards Lifesciences (EW) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Edwards Lifesciences' Q4 Earnings on Deck: Here's What to Expect
EW gears up for Q4 earnings as investors watch TAVR momentum, fast-growing TMTT sales and steady surgical heart demand.
Beyond Biotech—3 Healthcare Stocks for Growth-Minded Investors
Healthcare stocks rallied in 2025, breaking a two-year slump as investors chased steadier rates, better valuations, and improving earnings. The problem: mid-single-digit gains still lagged tech, leaving the sector feeling like a missed opportunity.
Is it Apt to Hold Edwards Lifesciences Stock in Your Portfolio Now?
EW benefits from strong TAVR and TMTT momentum, but macro pressures and FX headwinds cloud the near-term outlook.
Edwards Lifesciences Corporation (EW) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Edwards Lifesciences Corporation (EW) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
EW Wins FDA Approval for SAPIEN M3 as First Transseptal TMVR Therapy
Edwards Lifesciences wins FDA approval for SAPIEN M3, the first transseptal TMVR, expanding minimally invasive options for high-risk mitral regurgitation patients.
